Compare OLED & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLED | DNLI |
|---|---|---|
| Founded | 1985 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.4B |
| IPO Year | 1996 | 2017 |
| Metric | OLED | DNLI |
|---|---|---|
| Price | $75.38 | $18.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 20 |
| Target Price | ★ $113.82 | $35.75 |
| AVG Volume (30 Days) | 699.8K | ★ 1.7M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | ★ 9.25 | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $650,611,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.56 | $156.11 |
| P/E Ratio | $41.26 | ★ N/A |
| Revenue Growth | ★ 0.45 | N/A |
| 52 Week Low | $70.77 | $13.75 |
| 52 Week High | $153.38 | $27.30 |
| Indicator | OLED | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 30.82 |
| Support Level | $73.23 | $18.07 |
| Resistance Level | $81.15 | $20.84 |
| Average True Range (ATR) | 2.54 | 0.73 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 47.86 | 8.68 |
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. The large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.